Oncodesign Precision Medicine (XPAR:ALOPM) Debt-to-EBITDA : -1.16 (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Oncodesign Precision Medicine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.39 Mil. Oncodesign Precision Medicine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €7.20 Mil. Oncodesign Precision Medicine's annualized EBITDA for the quarter that ended in Dec. 2024 was €-6.53 Mil. Oncodesign Precision Medicine's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was -1.16.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Oncodesign Precision Medicine's Debt-to-EBITDA or its related term are showing as below:

XPAR:ALOPM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.81 Med: -0.93 Max: -0.51
Current: -1.04

During the past 5 years, the highest Debt-to-EBITDA Ratio of Oncodesign Precision Medicine was -0.51. The lowest was -1.81. And the median was -0.93.

XPAR:ALOPM's Debt-to-EBITDA is ranked worse than
100% of 293 companies
in the Biotechnology industry
Industry Median: 1.15 vs XPAR:ALOPM: -1.04

Oncodesign Precision Medicine Debt-to-EBITDA Historical Data

The historical data trend for Oncodesign Precision Medicine's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Debt-to-EBITDA Chart

Oncodesign Precision Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-EBITDA

-0.51

-0.81

-1.81

-0.93

-1.04

Oncodesign Precision Medicine Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-EBITDA	Get a 7-Day Free Trial			0.56	-0.27	-0.91	-	-1.16

Competitive Comparison of Oncodesign Precision Medicine's Debt-to-EBITDA

For the Biotechnology subindustry, Oncodesign Precision Medicine's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncodesign Precision Medicine's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's Debt-to-EBITDA falls into.

Save Embed

;

Save Embed

;

Oncodesign Precision Medicine Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Oncodesign Precision Medicine's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.385	+	7.196)	/	-7.264
	=	-1.04

Oncodesign Precision Medicine's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.385	+	7.196)	/	-6.528
	=	-1.16

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2024) EBITDA data.

Oncodesign Precision Medicine (XPAR:ALOPM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Oncodesign Precision Medicine Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncodesign Precision Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

ZR8:Germany

Address

18 rue Jean Mazen, Dijon, FRA, 21000

Website

https://www.opm.oncodesign.com

Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine Headlines

No Headlines